BioNexus Gene Lab (BGLC) Stock Price, News & Analysis

Company Overview

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Key Stats

• Today's Range: $2.81 to $3.05
• 50-Day Range: $2.17 to $4.35
• 52-Week Range: $2.01 to $8.40
• Volume: 6,821 shs
• Average Volume: 278,821 shs
• Market Capitalization: $5.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BGLC Stock Analysis - Frequently Asked Questions

How have BGLC shares performed this year?

BioNexus Gene Lab's stock was trading at $2.7970 at the beginning of 2025. Since then, BGLC stock has increased by 4.4% and is now trading at $2.92.
View the best growth stocks for 2025 here.

How were BioNexus Gene Lab's earnings last quarter?

BioNexus Gene Lab Corp. (NASDAQ:BGLC) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.03) earnings per share for the quarter. BioNexus Gene Lab had a negative trailing twelve-month return on equity of 24.18% and a negative net margin of 22.85%.

When did BioNexus Gene Lab's stock split?

BioNexus Gene Lab shares reverse split on the morning of Monday, April 7th 2025. A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did BioNexus Gene Lab IPO?

BioNexus Gene Lab (BGLC) raised $5 million in an initial public offering on Thursday, July 20th 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Network 1 Financial Securities served as the underwriter for the IPO.

How do I buy shares of BioNexus Gene Lab?

Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioNexus Gene Lab own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNexus Gene Lab investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BGLC
• CIK: 1737523
• Web: www.bionexusgenelab.com
• Phone: 60-1-2212-6512
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.60 million
• Net Margins: -22.85%
• Pretax Margin: -23.03%
• Return on Equity: -24.18%
• Return on Assets: -20.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.19
• Quick Ratio: 3.44

Sales & Book Value

• Annual Sales: $9.51 million
• Price / Sales: 0.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.63 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 1,800,000
• Free Float: 1,784,000
• Market Cap: $5.18 million
• Optionable: Not Optionable
• Beta: 5.60